Antonio Boccazzi Clinica Pediatrica 2.a - Milano DRUG RESISTANCE Pharmacological aspects • Minimize the time that suboptimal drug levels are present by thoughful attention to dosing. • Clinicians need to consider pharmacodynamic and pharmacokinetic properties when choosing an antibiotic therapy • Choosing the right dose and dose interval may be critical to achieving optimal clinical responses and preventing the emergence of resistant pathogens. J.J. Schentag, 1998; D.G. Burgess, 1999 Terapia empirica Terapia ragionata Terapia a casaccio STA AUMENTANDO L’IMPORTANZA DI MYCOPLASMA PN. ?? L’ESEMPIO DELL’ENCEFALITE Mycoplasma Pneumoniae: The Most Common Cause of Pediatric Encephalitis? Posted 01/02/2008 William T. Basco, Jr, MD, FAAP Author Information Pediatric Encephalitis: What Is the Role of Mycoplasma Pneumoniae? Christie LJ, Honarmand S, Talkington DF, et al Pediatrics. 2007;120:305-313 Abbiamo bisogno dei chinoloni in pediatria ? RESISTENZA DI S.PNEUMONIAE “PORTATO” IN NASOFARINGE IN ITALIA (242 ceppi – 2799 bambini) PENICILLINA 100 80 60,4 56,3 60 40 MACROLIDE 52,1 44,6 25,9 7,6 20 5,9 9,1 0 <2 2-5 >5 totale Marchisio et al, Emerg Infect Dis,2002 anni Vaccino anti-pneumococco e modificazione dell’etiologia di OMA 1992-98 Pre-vax SP 2000-2003 Post-vax SP 48% 31% Pen-I 16% 13% Pen-R 9% 6% Vax-types 70% 36% Vax-related types 8% 32% 41% 56% 56% 64% S.pneumoniae H.influenzae B.la pos Block S. Pediatr Infect Dis J sept. 04 pag.829 Vi sono novità nell’etiologia dell’OMA ? 1995-7 1998-2000 2001-03 (vax anti-SP) Timpanocentesi in OMA persistente o fallimenti terapeutici 16.2% 16.1% 12.3% * MEF 48% 44% 31% 38% 43% 51% * *** SP H.flu * Riduzione del 24% in 2001-03 vs altri periodi Riduzione p=0.017 Incremento p=0.012 Incremento di SP Pen-S p=0.17 Casey and Pichichero, Pediatr Infect Dis J Sept 04, pag 824 IN ARRIVO ALLARGAMENTO SIEROTIPI DI SP VAX ANTI-H.FLU non CAPSULATO Pharmacological aspects for emergence of resistance PHARMACOKINETIC • Insufficient antibiotic concentration at the site of infection PHARMACODYNAMIC • Unsuitable dose • Too long intervals between administrations • Short treatment duration Continuation of the ingestion process Rohde, Chhatwal, Kaplan, 2004 GABHS INTERNALIZATION /R Biofilm Sociomicrobiologia Pseudomonas aeruginosa Staph aureus Haemophilus influenzae S.Pneumoniae possono formare biofilm che sono inattaccabili da • anticorpi • fagociti Where are Biofilms to be found in chronic/recurrent infections? ENT: Pharyngotonsillitisitis, acute otitis media, rhino-sinusitis, otitis media with effusion, cholesteatoma ENT DEVICE-ASSOCIATED INFECTIONS: Tympanostomy tubes; endotracheal tubes Costerton et al., Science, 2002; Chole et al., Arch. Otolaryngol. Head & Neck Surg., 2003; Post et al., Curr. Opin. Otolaryngol. Head & Neck Surg., 2004 Bacterial biofilms in adults with chronic sinusitis undergoing sinus surgery Present in 14 of 18 specimens Sanderson AR, Laryngoscope 2006 Hall-Stoodley L et al, JAMA 2006; 296:202 Tempo in cui le concentrazioni rimangono sopra la MIC in S. pneumoniae penicillino sensibile (pen S) o penicillino intermedio (pen I) di vari antibiotici betalattamici orali Farmaco Co-Amoxiclav Cefaclor Cefuroxime Cefixime Ceftibuten Cefpodoxime Dose 500 mg x3 500mg x3 500 mg x2 400 x1 400 x1 200x2 R Auckenthaler . JAC- 2000 pen S MIC90(mg/L) / T>MIC (%) Pen I MIC90(mg/L )/ T>MIC (%) 0.125/ 113.8 1/49.3 0.25/73.1 1/48.1 8/19.9 0.125/112.6 1/65 16/11.8 2/43.1 16/0 16/9.9 1/52.6 Tempo in cui le concentrazioni rimangono sopra la MIC in H. influenzae di vari antibiotici betalattamici orali Farmaco CoAmoxiclav Cefaclor Cefuroxime Cefixime Ceftibuten Cefpodoxime Dose 500 mg x3 500mg x3 250 mg x2 400 x1 400 x1 200x2 R Auckenthaler . JAC- 2000 b-lattamasi + MIC90(mg/L)/ T>MIC (%) b-lattamasi MIC90(mg/L)/ T>MIC (%) 1/65 32/2.4 2/43.1 0.25/81.5 0.25/69.9 0.25/92.6 1/65 16/11.8 2/43.1 0.25/81.5 0.25/69.9 0.25/92.6 Tempo in cui le concentrazioni rimangono sopra la MIC in M.catarrhalis di vari antibiotici betalattamici orali Farmaco Co-Amoxiclav Cefaclor Cefuroxime Cefixime Ceftibuten Cefpodoxime Dose b-lattamasi + MIC90(mg/L)/ T>MIC (%) 500 mg x3 500mg x3 250 mg x2 400 x1 400 x1 200x2 0.25/97.5 1/49.3 2/43.1 0.5/64.8 4/29.9 0.5/72.6 R Auckenthaler . JAC- 2000 Tempo in cui le concentrazioni rimangono sopra la MIC in S. pyogenes di vari antibiotici betalattamici orali Farmaco Co-Amoxiclav Cefaclor Cefuroxime Cefixime Ceftibuten Cefpodoxime Dose 500 mg x2 500mg x3 250 mg x2 400 x1 400 x1 200x2 MIC90(mg/L)/ T>MIC (%) OK MEF concentrations of azithromycin in total or free cell fraction C+ C- BAS 0 0 4h 0.38 + 0.24 0.11 + 0.04 12h 0.9 + 0.3 0.12 + 0.08 24h 1.05 + 0.3 0.23 + 0.12 Scaglione et al 1998 Cefixime Rapporto MEF/MIC90 (media volte) C+ C- 4.8 12.8 Bla pos M.catarrhalis S.pneumoniae Pen-S 2.4 2.4 6.4 6.4 2.4 6.4 Pen-I 0.3 0.8 H.influenzae Bla neg Cmax MEF 1.2 mg/L + 0.6 SD (C+) e 3.2 mg/L + 1.4 SD (C-) (10) C+ titolata con componente cellulare MEF C- titolata senza componente cellulare MEF Boccazzi et al, 2003 S.pyogenes (1056) Evolution of macrolide-resistance in Italy %R 45 * 40 PROTEKT ITALY * 35 (2002) 30 * 25 20 15 10 * 5 0 1993 1995 1996 1997 1998 1999 2000 2002 * two studies. Schito et al., JAC, 1997; Varaldo et al., CID, 1999; Crotti, Medori and D’Annibale, GIMMOC 2001; Rondini, GIMMOC 2001; Schitot et al.,GIMMOC, 2003 S.pneumoniae (848) Trend of penicillin-resistance in Italy %R 25 PROTEKT ITALY (2002) 20 15 H-L L-L 10 5 0 1992 1995 1996 1997 1998 1999 2000 2001 2002 Felmingham et al., JAC, 1996; Felmingham et al., JAC, 2000; Marchese et al., MDR 2001; Marchese et al., SIM Congress, 2002; Schito et al., ICAAC, 2003 S. pneumoniae Trend della eritromicino-resistenza in Italia %R 45 PROTEKT ITALIA (2002) 40 35 30 25 20 15 10 5 0 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 Felmingham et al., JAC, 1996; Felmingham et al., JAC, 2000; Marchese et al., MDR 2001; Marchese et al., SIM Congress, 2002 Correlazione tra resistenza (%) di 4 antibiotici nei tre differenti fenotipi di S. pneumoniae (552 ceppi) in Italia nel 2000 Percentuale di ceppi resistenti a: Fenotipo (n, %) E SXT TE LEV PenS (461, 83,5) 34,9 34,5 25,6 0,2 PenI 50,0 41,2 42,6 0 43,5 87,0 26,1 0 (68, 12,3) PenR (23, 4,2) eritromicina (E), cotrimossazolo (SXT), tetraciclina (TE), levofloxacina (LEV) Dead Bugs Don’t Mutate C.W. Stratton, 2003 Mutant prevention concentration (MPC) Definizione Concentrazione minima di antibiotico in grado di prevenire la crescita di ceppi batterici resistenti (inoculo in piastra di 1010 batteri) Fornisce informazioni sul possibile sviluppo di resistenza Drlica e Schmitz, 2002 Serum or tissue drug concentration Mutant Selection Window (MSW) Above MPC – both susceptible and first-step resistant cells inhibited – no selective amplification of resistance subpopulation. MPC MSW MSW - susceptible cells inhibited. - first step resistant cells not inhibited. - selective amplification of resistant subpopulation MIC Sub MIC – neither susceptible nor firststep resistant mutants inhibited – no selective amplification of resistant subpopulation. Time post-administration Blondeau et al, 2004, J.Chemo Correlazione tra le concentrazioni sieriche di moxifloxacina e levofloxacina ed MPC vs S. pneumoniae Moxifloxacina Levofloxacina 8 8 7 7 6 6 5 Cmax=4,5ug/ml 4 3 3 2 2 1 0 1 Cmax=5,7ug/ml 5 4 MPC90=2ug/ml Finestra di selezione dei mutanti MPC90=8ug/ml Finestra di selezione dei mutanti MIC90=1ug/ml 1 MIC90=0,25ug/ml 6 12 Ore 18 24 0 1 6 12 Ore 18 24 Wise 1999, Blondeau et al. 2001, Hansen et al. 2002, Hansen et al. 2003 Correlazione tra sviluppo di resistenze in P. aeruginosa e utilizzo di levofloxacina e ciprofloxacina Ciprofloxacina uso Levofloxacina uso Ciprofloxacina sensibilità Ospedale di Danbury (Danbury, USA) 120 84 82 100 80 78 80 76 72 Uso (%) 40 70 68 20 66 0 64 01 98 02 98 03 98 04 98 01 99 02 99 03 99 04 99 01 00 02 00 03 00 04 00 01 01 02 01 Sensibilità (%) 74 60 03 01 Iannini, Tillotson 2001 Uso di fluorochinoloni e sviluppo di resistenza vs S. pneumoniae (USA) Levofloxacina 35 6 30 5 25 4 20 3 15 2 10 1 0 5 0.9 1988 1.2 1989 1993 *IR: Infezioni Respiratorie 1994 1.6 1995 n=1527 (30) 1996 1997 1.4 1998 n=1601 (34) 1999 3.4 2000 n=1531 (33) 2001 0 2002 n=1934 (45) Prescrizioni per 1000 pazienti per IR* Pneumococchi con ridotta suscettibilità ai FQs (%) Ciprofloxacina Comparative MIC distribution for azalide/macrolide compounds against clinical isolates of S. pneumoniae (n=178). Drug Concentration (ug/ml) Compound Azithromycin <0.031 0.063 12 58 0.125 0.25 0.5 1 >2 68 11 1 2 26 (BP <0.5/ug/ml) (16%) Clarithormycin 120 31 1 1 1 5 (BP <0.25 ug/ml) Erythromycin (14%) 8 89 46 7 0 1 (BP <0.25 ug/ml) Telithromycin (n=372) 19 25 (15%) 331 11 15 8 4 3 (<1%) Blondeau et al, Nurnberg Germany Sept/04:ECCMID, 2005 Comparative RPC distribution for azalide/macrolide compounds against clinical isolates of S. pneumoniae (n=178). Drug Concentration (ug/ml) Compound Azithromycin <0.125 1 0.25 0.5 1 >2-8 9 38 50 80 (BP <0.5/ug/ml) (73%) Clarithromycin 79 44 14 11 (BP <0.25 ug/ml) Erythromycin (23%) 18 60 41 22 (BP <0.25 ug/ml) Telithromycin 30 37 (33%) 208 16 14 (7 isolates >0.5ug/ml) (n=245) Blondeau et al, Nurnberg Germany Sept/04:ECCMID, 2005 Correlazione tra prescrizione antibiotica nell’OMA e incidenza della mastoidite acuta Tasso di prescrizione antibiotica Incidenza per 100.000 p.a. OLANDA 31% 3.8 NORVEGIA 67% 3.5 DANIMARCA 76% 4.2 USA 96% 2.0 INGHILTERRA 99% 1.2 PAESE Van Zuijlen, 2001 IL PUZZLE DELL’ANTIBIOTICOTERAPIA SITO ANTIBIOTICO BATTERI + MIC PAZIENTE Role of Bacterial Interference and beta-Lactamase-Producing Bacteria in the Failure of Penicillin to Eradicate Group A Streptococcal Pharyngotonsillitis Brook, Itzhak MD, MSc; Gober, Alan E. MD From the Departments of Pediatrics, Georgetown and George Washington Universities Schools of Medicine, Washington, DC. Archives of Otolaryngology-Head & Neck Surgery 121(12), December 1995, pp 1405-1409 Archives of Otolaryngology-Head & Neck Surgery 121(12), December 1995, pp 1405-1409 Archives of Otolaryngology-Head & Neck Surgery 121(12), December 1995, pp 1405-1409 Archives of Otolaryngology-Head & Neck Surgery 121(12), December 1995, pp 1405-1409